New Data Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) in Evaluation of Hypertension
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new data from Duke University Medical Center that was presented Saturday, November 10, 2018 at the American Heart Association Scientific Sessions in Chicago, IL. The study titled “Blood Volume and Analysis in Patients with Hypertension,” looked at the three main components of blood in adults with hypertension; total blood volume (TBV), red blood cell volume (RBV) and plasma volume (PV) to test whether there is a relationship between these blood volume parameters and standard blood pressure (SBP) and to see whether there is a correlation with race. Blood volume parameters were measured with Daxor’s BVA-100 and blood volumes were expressed as a percent deviation from the patient’s ideal volumes.
Marat Fudim, M.D., lead author of the study commented, “Our findings support the need for more detailed analysis of blood volume type, as this could help guide anti-hypertensive management.” The results showed that patients with hypertension have a wide variation in TBV, RBCV and PV and that SBP does not correlate with direct blood volume measurement. Blacks had lower blood volume parameters compared to Non-Blacks (p<0.001), despite higher SBP (159 mmHg, SD +/- 98 vs.142 mmHg, SD +/- 72). “Volume management is an essential component of anti-hypertensive therapy -- progressive hypertension often leads to stroke, heart failure and kidney failure, taking a tremendous toll on the quality of life for millions of adults every year,” said Michael Feldschuh, CEO of Daxor Corporation. This study adds to the wide body of evidence that proves blood volume heterogeneity is common in these medical conditions but not properly detected through conventional pressure metrics. The BVA-100 provides a simple, rapid, and accurate means to directly measure blood volume to help physicians best individualize treatment to ensure better patient outcomes and improve their quality of life.”
About Daxor Corporation
Daxor Corporation is an innovative medical instrumentation and biotechnology company. We manufacture the BVA-100 Blood Volume Analyzer, the only clinically available, rapid and accurate diagnostic which provides rapid direct measurement of a patient’s blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. Ultimately the company’s mission is to help hospitals and physicians incorporate Daxor’s BVA-100 diagnostic to significantly improve the quality of patient care. For more information please visit our website at http://www.daxor.com.
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr. Managing PartnerCORE IR561-479-8566 firstname.lastname@example.org